Study design and swimmerplot. (A) Study design with triple combination of GIVe from cycles 1 to 6, ibrutinib and venetoclax from cycles 7 to 12, and ibrutinib until cycle 15, in case of CR and uMRD at cycles 9 and 12. Otherwise, ibrutinib was scheduled to continue until cycle 36. (B) Treatment disposition of all patients according to genetics (del[17p] and TP53 mutation, sole del[17p], sole TP53 mutation). Gray lines indicate the duration of treatment, and blue lines indicate the follow-up period. Thirty-four of 41 patients reached final restaging. The symbols at the end of the gray lines define reasons for treatment discontinuation and time point of final restaging (between cycles 14 and 15 because of different timing of response assessment). The red X symbols indicate 7 disease progressions. Black crosses indicate 3 deaths.